Saniona AB (30S) Stock Price & Analysis
30S Stock Chart & Stats
- Day’s Range
- EUR 0.99 - EUR 1.01
- 52-Week Range
- EUR 0.78 - EUR 2.58
- Previous Close
- EUR 1.01
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 140.27M
- Enterprise Value
- EUR 1.32B
- Total Cash (Recent Filing)
- EUR 486.31M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- 7.9
- Beta
- 0.70
- Next Earnings
- Nov 26, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Profitability
The sharp shift from heavy losses in 2021–2023 to very high profitability in 2025 and 2026 TTM demonstrates substantial recent earnings power. If supported by recurring business activity, these margins can fund development, strengthen resilience, and support continued investment in the pipeline.
Debt-free Balance Sheet
A debt-free structure materially reduces interest burden, refinancing exposure, and financial stress while giving Saniona more flexibility to fund research and development. The strong current equity base also provides a more resilient platform for advancing programs through uncertain biotechnology development cycles.
Positive Cash Generation
Positive operating and free cash flow across the latest three reported periods is a meaningful sign that recent earnings are producing internal funding rather than requiring continual external financing. This supports ongoing program development and improves the company’s ability to manage investment decisions independently.
Bears Say
Revenue Volatility
The sharp latest TTM revenue decline following strong prior-year growth makes the current earnings base difficult to forecast. In a biotech model that may include milestones or licensing revenue, inconsistent top-line performance can weaken visibility into recurring operations and reduce confidence in sustaining recent profitability.
Cash Conversion Below Earnings
Although free cash flow remains positive, its level below net income indicates that reported profitability is not converting fully into cash. Choppy annual cash-flow growth further reduces predictability and may limit the reliability of internally generated funds for pipeline advancement and other long-term priorities.
Historical Capital Instability
The transition from leverage in 2022 and negative equity in 2023 to a debt-free, positive-equity position shows that financial strength has not been consistently stable. This history indicates the company has previously faced substantial balance-sheet pressure, an important risk when evaluating durability over several quarters.
Saniona AB News
30S FAQ
What was Saniona AB’s price range in the past 12 months?
What is Saniona AB’s market cap?
When is Saniona AB’s upcoming earnings report date?
How were Saniona AB’s earnings last quarter?
Is Saniona AB overvalued?
Does Saniona AB pay dividends?
What is Saniona AB’s EPS estimate?
How many shares outstanding does Saniona AB have?
What happened to Saniona AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Saniona AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Saniona AB
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas Feldthus
- Employees
- 44
- Website
- www.saniona.com
- Address
- Murervangen 42, Glostrup, CD, 2600, DK
Saniona AB (30S) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 3 | 9 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 8 | 0 | 4 |
